Soleno Therapeutics (SLNO)
(Delayed Data from NSDQ)
$41.16 USD
-0.01 (-0.02%)
Updated May 24, 2024 04:00 PM ET
After-Market: $41.04 -0.12 (-0.29%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Soleno Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 41 | 24 | 32 | 36 | 23 |
Income After Depreciation & Amortization | -41 | -24 | -32 | -36 | -23 |
Non-Operating Income | 2 | 0 | 1 | 12 | -7 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -39 | -24 | -31 | -25 | -31 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -39 | -24 | -31 | -25 | -31 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -39 | -24 | -31 | -25 | -31 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -39 | -22 | -30 | -34 | -22 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 2 | 2 | 2 |
Income After Depreciation & Amortization | -41 | -24 | -32 | -36 | -23 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 16.49 | 8.40 | 5.32 | 4.18 | 2.28 |
Diluted EPS Before Non-Recurring Items | -2.36 | -2.87 | -6.00 | -5.85 | -10.50 |
Diluted Net EPS (GAAP) | -2.36 | -2.87 | -5.85 | -5.85 | -13.49 |
Fiscal Year end for Soleno Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 23.47 | 13.91 | 10.38 | 8.62 | 8.47 |
Income After SG&A, R&D, and Dept/Amort Expenses | -23.47 | -13.91 | -10.38 | -8.62 | -8.47 |
Non-Operating Income | 2.08 | 2.61 | -0.48 | 0.15 | 0.11 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -21.40 | -11.30 | -10.86 | -8.48 | -8.36 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -21.40 | -11.30 | -10.86 | -8.48 | -8.36 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -21.40 | -11.30 | -10.86 | -8.48 | -8.36 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 36.21 | 34.44 | 11.44 | 10.42 | 9.45 |
Diluted EPS Before Non-Recurring Items | -0.59 | -0.33 | -0.95 | -0.81 | -0.88 |
Diluted Net EPS (GAAP) | -0.59 | 0.28 | -0.95 | -0.81 | -0.88 |